gms | German Medical Science

87th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

04.05. - 07.05.2016, Düsseldorf

Article

Send article

Mixed adenoneuroendocrin carcinoma in the oral cavity

Meeting Abstract

Search Medline for

  • corresponding author Gabriella Kecskés - Västerås Central Hospital, Department of Otorhinolaryngology, Västerås, Sweden
  • Anders Westernborn - Örebro University Hospital, Dep.of Otorhinolaryngology, Örebro, Sweden
  • Johan Reizenstein - Örebro University Hospital, Department of Oncology, Örebro, Sweden

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. 87. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. Düsseldorf, 04.-07.05.2016. Düsseldorf: German Medical Science GMS Publishing House; 2016. Doc16hnod177

doi: 10.3205/16hnod177, urn:nbn:de:0183-16hnod1775

Published: March 30, 2016

© 2016 Kecskés et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Introduction: Mixed adenoneuroendocrin carcinoma (MANEC) has a phenotype when neuroendocrin tumor coexists with adenocarcinoma. The incidence of MANEC has not yet been epidemiologically analyzed since it is one of the rarest types of neuroendocrine tumor, only case reports can be found in the literature. The few reported cases was all found in the gastrointestinal tract and none of them was ever decribed in the oral cavity.

Case report: 68-year–old male patient presenting with voluminous lesion in the oral cavity, below the tongue involving the floor of the mouth. CT showed a 4.5 cm large bulky resistens. Preoperative core needle biopsy suggested a neuroendocrin malignancy which has been surgically removed. Histopathologic examination revealed a MANEC tumor. He did not receive any chemotherapy. The patient is clinically and radiologically tumor-free at 17 month postoperatively.

Discussion: The optimal strategy of management of MANEC is largely unknown due to the rarity of these neoplasm. I am eager to discuss any further treatment options proposed by the participants.

Der Erstautor gibt keinen Interessenkonflikt an.